dual antiplatelet therapy

Trombosis-post-TAVI

Ischemic and Bleeding Risk After Primary Angioplasty

Patients with ST-segment elevation myocardial infarction who undergo primary angioplasty are at high risk for both ischemic and bleeding events, which affect significantly both morbidity and mortality. An optimal selection of antithrombotic therapies in terms of strength and duration must take into account the timing for the procedure, since the risk for these complications may<a href="https://solaci.org/en/2017/11/22/ischemic-and-bleeding-risk-after-primary-angioplasty/" title="Read more" >...</a>

DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study,&nbsp;dual antiplatelet therapy&nbsp;with&nbsp;ticagrelor&nbsp;and&nbsp;aspirin&nbsp;improves vein graft patency a year after surgery without increasing the risk for major bleeding. &nbsp; Treatment with the P2Y12 inhibitor ticagrelor in combination with aspirin has been widely accepted for patients with acute coronary syndrome undergoing angioplasty. However, there were no related data regarding surgical revascularization. Read also:&nbsp;&#8220;Ticagrelor<a href="https://solaci.org/en/2017/11/16/dacab-ticagrelor-and-aspirin-improve-vein-graft-patency/" title="Read more" >...</a>

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related<a href="https://solaci.org/en/2017/11/06/tct-2017-prevail-final-outcomes-of-the-watchman-device/" title="Read more" >...</a>

TCT 2017 | Estudio TRI-REPAIR y estudio FORMA: nuevos dispositivos para la “válvula olvidada”

TCT 2017 | The TRI-REPAIR and the FORMA Trials: New Devices for the “Forgotten Valve”

Courtesy of SBHCI. Two new transcatheter treatments for severe or massive functional tricuspid regurgitation have showed good results at 30&nbsp;days, according to their feasibility studies. The long-forgotten tricuspid valve has been gaining more attention with research linking tricuspid regurgitation to an increase in mortality. &nbsp; Early studies used devices originally designed for the mitral or<a href="https://solaci.org/en/2017/11/06/tct-2017-the-tri-repair-and-the-forma-trials-new-devices-for-the-forgotten-valve/" title="Read more" >...</a>

Las plataformas bioabsorbibles no deben ser elegidas por sobre los DES actuales

Bioresorbable Scaffolds Must Not Be Chosen Over Current DES

Although there are 4 approved bioresorbable scaffolds (BRS) in Europe, experts suggest that current drug-eluting stents (DES) are the best option for coronary angioplasty. These new guidelines jointly published by the European Society of Cardiology (ESC) and the Association of Percutaneous Cardiovascular Interventions (EAPCI) are an update on the use of BRS in clinical practice<a href="https://solaci.org/en/2017/10/19/bioresorbable-scaffolds-must-not-be-chosen-over-current-des/" title="Read more" >...</a>

These Are the Thrombosis Predictors for Absorb Bioresorbable Scaffolds

J Am Coll Cardiol Intv has recently published a special issue on bioresorbable scaffolds. Abbott&#8217;s decision to pull Absorb off the market probably prompted the fast publishing of all related articles sent to the journal. Bioresorbable scaffolds were developed in hopes that they would reduce the rates of events per year 1&nbsp;year post-implantation by 1.5%-3%<a href="https://solaci.org/en/2017/09/28/these-are-the-thrombosis-predictors-for-absorb-bioresorbable-scaffolds/" title="Read more" >...</a>

Very Late Thrombosis in Bioresorbable Scaffolds

The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors thrombosis, leaving the vessel vulnerable to very late thrombosis. Dual antiplatelet therapy, a better implantation technique, and several improvements in new drug-eluting stents (DES) (thinner struts, and higher polymer stability and biocompatibility) have lowered significantly the incidence of<a href="https://solaci.org/en/2017/09/26/very-late-thrombosis-in-bioresorbable-scaffolds/" title="Read more" >...</a>

bioresorbable-vascular-scaffold

Polymer-Free DES Also Show Efficacy in Anticoagulated Patients with High Risk for Bleeding

Patients who receive chronic anticoagulation therapy and then undergo angioplasty are frequently discharged on a triple anti-thrombotic scheme that usually includes&nbsp;aspirin, clopidogrel, and warfarin. The optimal duration of this indication remains unclear, particularly for patients at high bleeding risk. According to expert consensus, patients receiving chronic anticoagulation may receive from 1 to 12&nbsp;months of dual<a href="https://solaci.org/en/2017/09/08/polymer-free-des-also-show-efficacy-in-anticoagulated-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

La angioplastia “ad hoc” durante el TAVI no impacta en su seguridad ni en resultados a largo plazo

“Ad Hoc” PCI during TAVR: No Impact on Safety or Long Term Outcomes

According to a recent study published in&nbsp;Circulation Cardiovascular Interventions, screening for coronary artery disease&nbsp;(CAD) with an invasive coronary angiography&nbsp; (as part of the protocol prior TAVR) &nbsp;and performing PCI and TAVR&nbsp;in the same session, has no impact on periprocedural safety or on long term outcomes. Study outcomes offer new hope, especially as regards using TAVR<a href="https://solaci.org/en/2017/09/06/ad-hoc-pci-during-tavr-no-impact-on-safety-or-long-term-outcomes/" title="Read more" >...</a>

Los stent autoxpandibles son superiores a los de balón expandibles en el territorio ilíaco

Self-Expanding Stents Are Superior to Balloon-Expandable Stents in the Iliac Arteries

Courtesy of Dr. Carlos&nbsp;Fava. Severe atherosclerotic disease in&nbsp;iliac arteries is experienced by 15% of all men and 5% of all women. TAC&nbsp;II recommends&nbsp;angioplasty for type-A, -B, and -C lesions. As regards stent type, self-expanding stent (SE, more elasticity) vs. balloon-expandable stent (SB, more radial strength), Reekers indicates superior target lesion&nbsp;revascularization (TLR) with SE. However, there<a href="https://solaci.org/en/2017/09/05/self-expanding-stents-are-superior-to-balloon-expandable-stents-in-the-iliac-arteries/" title="Read more" >...</a>

Top